Abstract
A broad phase II study of cis-dichlorodiammineplatinum(II) was conducted. Eight patients with stage IVB Hodgkin's disease were studied. Four of these patients attained an objective partial remission of 7-19+ weeks' duration. The usual time to the occurence of a ≥25% response was 1 week. This drug is active in far-advanced Hodgkin's disease with a projected lower limit of response rate from 19% to 21%.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 763-766 |
| Number of pages | 4 |
| Journal | Journal of Fluid Mechanics |
| Volume | 63 |
| Issue number | 5 |
| State | Published - 1979 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Phase II study of cis-dichlorodiammineplatinum(II) in stage IVB Hodgkin's disease'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS